Top Markets
#1 bitcastle Token bitcastle Token +140.78%
#2 MowCat MowCat +87.26%
#3 MarsCoin MarsCoin +56.23%
#4 Palladium Network Palladium Network +53.22%
#5 Siren Siren +29.86%
#6 Useless Coin Useless Coin +24.19%
#7 Bedrock Bedrock +24.14%
#8 edgeX edgeX +18.66%
#9 Pons Pons +16.54%
#10 Zest Protocol Zest Protocol +16.15%
Coin of the day
bitcastle Token bitcastle Token
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Innate Pharma S.A. Innate Pharma S.A.

Innate Pharma S.A.

IPH
Classement en actions #18332
Innate Pharma S.A. is a biotechnology firm dedicated to the discovery,... Innate Pharma S.A. is a biotechnology firm dedicated to the discovery, development, and commercialization of innovative antibody-based therapies, primarily for cancer indications, operating both in France and internationally. The company's pipeline includes several key drug candidates: Lacutamab (IPH4102), an anti-KIR3DL2 antibody, is currently in Phase II clinical trials for treating cutaneous T-cell and peripheral T-cell lymphoma, as well as refractory Sézary syndrome. Monalizumab, an immune checkpoint inhibitor, is undergoing Phase III evaluation for advanced solid tumors, encompassing colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401), a monoclonal antibody designed to block C5a binding to C5aR1, is advancing through Phase II studies for conditions such as COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases. IPH5201, a blocking antibody, is in Phase I clinical trials, aiming to modulate the CD39 immunosuppressive pathway. IPH5301, an anti-CD73 antibody, targets the immunosuppressive adenosine pathway to foster anti-tumor immunity. IPH6101, an NKp46-based NK cell engager, is being developed for the creation and assessment of up to two bispecific NK cell engagers. Beyond clinical stages, their preclinical programs feature IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), along with the IPH62 and IPH64 programs. Innate Pharma S.A. maintains strategic alliances and licensing deals with prominent pharmaceutical entities including AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, in addition to a co-development and licensing agreement with MedImmune Limited. The company was founded in 1999 and has its headquarters located in Marseille, France.
Prix de l'action
$2.15
Capitalisation boursière
$202.27M
Changement (1 jour)
0.89%
Changement (1 an)
-0.68%
Pays
FR
Échange Innate Pharma S.A. (IPH)

Catégorie

Healthcare
Nombre d'actions en circulation pour Innate Pharma S.A. (IPH)
Nombre d'actions en circulation au September 2026: 0
Selon les derniers rapports financiers et le cours de l'action de Innate Pharma S.A., le nombre actuel d'actions en circulation est de 0. À la fin de September 2026, l'entreprise avait 0 actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de Innate Pharma S.A. (IPH) de 2026 à 2026
Actions en circulation à la fin de chaque année
Année Actions en circulation Changez
Pas assez de données pour les dates fournies.
Actions en circulation pour des entreprises similaires ou concurrentes
Entreprise Actions en circulation Différence Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH